Tirzepatide levocarnitine is a compounded injectable formulation that combines two distinct compounds into a single weekly injection
Important safety considerations include: it is not recommended during pregnancy or breastfeeding
Specifically, on the 1 st physician visit (Week 0), the first fatigue score was recorded
The data shows that when taken in low and moderate dosages, ipamorelin causes mild side effects such as: Temporary redness, itching, or sensitivity at the site of the injection Dry mouth Nausea Weight gain, usually associated with increased muscle mass and body fat loss In rare cases, some severe side effects have been observed, including: Water retention Tingling/numbness in the hands and feet Insulin resistance Hypertension This indicates that researchers interested in experimenting with ipamorelin would be well-advised to exclude test subjects with pre-existing conditions such as diabetes and hypertension
Zhang D-M, Guo Z-X, Zhao Y-L, Wang Q-J, Gao Y-S, Yu T, et al